Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 29 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 2351–2400 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2351RCT2005

Ortega-González C, Luna S, Hernández L, Crespo G, Aguayo P, Arteaga-Troncoso G · J Clin Endocrinol Metab (2005)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Steady-state pharmacokinetics of a novel extended-release metformin formulation.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.

The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.

Metformin improves endothelial function in patients with metabolic syndrome.

Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome.

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

[Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.

Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Metformin monotherapy for type 2 diabetes mellitus.

Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study.

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes.

Bioequivalence studies with metformin: comparability of reference tablets from different origins.

Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.

Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.

[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].

Metformin as treatment for overweight and obese adults: a systematic review.

Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study.

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.

Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus.